Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New tactic: Warning letters to health care providers

This article was originally published in The Silver Sheet

Executive Summary

On Oct. 27, FDA sent warning letters to 17 ambulatory surgical centers that perform laser-assisted in situ keratomileusis (LASIK) procedures, citing the facilities for failure to develop, maintain and implement written Medical Device Reporting (MDR) procedures. (See "1Warning Letters") CDRH has also stepped up communications with health care facilities and professional societies to clarify the agency's requirements for MDR reporting. CDRH Office of Compliance Director Tim Ulatowski says it's "vitally important" that user facilities, and not just device manufacturers, comply with MDR regulations. Under the regulation, hospitals and other user facilities must submit a report to both FDA and the manufacturer when a device may have caused or contributed to a death. When it may have caused or contributed to a serious injury, the facility generally only needs to tell the manufacturer. "If the manufacturers aren't getting the reports and FDA is not getting the reports from user facilities when necessary, then the whole system breaks down, or is at least in jeopardy," Ulatowski says. "We need to be receiving these reports so we can properly assess in a post-market period how these devices that are involved in LASIK procedures are performing.

You may also be interested in...

FDA Warning Letters

WARNING LETTERS: Baxter citations follow FDA inspections at seven facilities; Philips failed to establish procedures for complaint handling and Medical Device Reporting, FDA says

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts